BioCryst Pharmaceuticals announces restructuring
BioCryst is streamlining its portfolio of antivirals in a bid to lower costs.
A bio pharma company has announced restructuring that will see it focus efforts on its antiviral programmes, following an assessment of all of its assets.
Based in Alabama, BioCryst Pharmaceuticals aims to significantly reduce its costs as part of the restructuring, as well as the scale of its organisation in line with a new streamlined portfolio.
The company will focus on advancing its hereditary angiodema programme, alongside its BCX4161 HAE and BCX4430 broad spectrum antivirals, and its BCX5191 hepatitis C treatment.
Jon Stonehouse, president and chief executive of BioCryst, said: "The strategic focus and restructuring announced today is based on an evaluation of our programmes and operations, following the setbacks in our peramivir and BCX5191 programmes, as well as the delay in our BCX4161 programme.
"The restructuring is a necessary but difficult measure that impacts many talented and dedicated BioCryst employees who will be leaving the company," he added. "We are grateful for their meaningful contributions and commitment over the years.
The compmany is currently conducting a study into the efficacy of low doses of BCX5191 in the treatment of the hepatitis C virus.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...